MGMT Protein Expression and Methylation in Tumors
Author Information
Author(s): Brell Marta, Ibáñez Javier, Tortosa Avelina
Primary Institution: Son Dureta University Hospital, Palma de Mallorca, Spain
Hypothesis
Is there a correlation between MGMT protein expression assessed by immunohistochemistry and MGMT promoter methylation determined by methylation-specific polymerase chain reaction?
Conclusion
MGMT protein expression assessed by IHC does not reliably reflect the promoter methylation status of MGMT, indicating that the two methods should not be used interchangeably in clinical diagnostics.
Supporting Evidence
- 52 studies met the inclusion criteria out of 254 identified.
- MGMT protein expression by IHC showed poor agreement with MSP results.
- Type of tumor was an independent covariate affecting accuracy estimates.
Takeaway
This study looked at how well two tests for a cancer-related protein match up. It found that one test doesn't always show the same results as the other, especially in brain tumors.
Methodology
A systematic review and meta-analysis comparing MGMT protein expression by IHC with MGMT promoter methylation by MSP in the same cohort of patients.
Potential Biases
Potential publication bias was indicated, as well as variability in interpretation of IHC results.
Limitations
Partial verification bias was not clearly avoided in many studies, and the assessment of the reference test was not always blinded.
Participant Demographics
The study included 2943 patients: 539 with primary brain tumors, 178 with brain metastases, and 2,226 with non-brain systemic cancer.
Statistical Information
Confidence Interval
95% CI[2.42-11.86]
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website